The Company licensed ABX203 from the Center for Genetic
Engineering and Biotechnology (CIGB)
in 2013, providing the Company with exclusive rights to market ABX203
in Europe, Australia, New Zealand, select Asian countries, and most of Africa. Abivax is currently conducting a Phase II/III trial evaluating the safety and efficacy of ABX203 for the treatment of patients with chronic hepatitis B. The trial is fully enrolled and the Company expects to report data in the fourth quarter of 2016.